- Home
- By Diseases
- Hereditary Ophthalmic Diseases
- Goldmann-Favre Syndrome (GFS)
We use cookies to understand how you use our site and to improve the overall user experience. This includes personalizing content and advertising. Read our Privacy Policy
Goldmann–Favre syndrome (GFS) is an uncommon autosomal recessive disorder of retinal dystrophy resulting from impaired development and/or function of cone photoreceptors. Protheragen, a leading provider of research services, offers a comprehensive suite of services for the development of diagnostics and therapeutics targeting Goldmann-Favre Syndrome (GFS).
Goldmann-Favre Syndrome (GFS) is an uncommon heritable disorder accompanied by severe night vision impairment as well as pronounced retinal degeneration. This syndrome stems primarily from mutations in the NR2E3 gene, which encodes a nuclear receptor associated with photoreceptor development and their functions. GFS syndrome is mostly perceived as a severe type of enhanced S-cone syndrome with profound visual impairment occurring early in life. Its manifestation includes nyctalopia and progressive constriction of the visual fields, and retinal degeneration, thus underscoring the need for active diagnostic and therapeutic approaches.
Fig. 1 Fundus photograph case analysis of Goldmann-Favre Syndrome (GFS). (Bansal M., et al., 2023)
The development of GFS is closely associated with the mutation of precursor genes NR2E3 found on chromosome 15q23. This gene encodes a transcription factor that governs the expression of specific genes of photoreceptors in the retina. The imbalance of photoreceptor's development because of mutation in NR2E3, gives rise to blue cones (S-cones) supersaturation while rods (R-cones) are functionally absent. This incorrect allocation of photoreceptors leads to derangement of normal architecture and functioning of retina, which causes gradual loss of vision and retinal degeneration. Histopathological studies have demonstrated a significant increase in blue cone opsins and a marked reduction in rod photoreceptors, further elucidating the molecular basis of this disorder.
Gene Therapy
Gene therapy offers a novel, promising avenue for GFS therapeutics by correcting the genetic anomaly. Approaches involve the introduction of functional copies of the NR2E3 gene into retinal cells through viral vectors like adeno-associated viruses (AAV). Preliminary research has illustrated the promise of this strategy in animal models. For instance, the administration of NR2E3 through AAV in GFS mouse models has demonstrated restoration of photoreceptor activity and preservation of retinal architecture, suggesting the beneficial prospects of gene therapy for this disorder.
Small Molecule Therapeutics
Small molecules can interact with particular pathways that are critical for the functioning and survival of photoreceptors. For example, some compounds which affect the Wnt signaling pathway have yielded positive results in preclinical assays regarding the supplementation of photoreceptor survival and the retardation of retinal degeneration. Furthermore, small molecules that act to inhibit apoptosis or enhance autophagy are likely to have neuroprotective properties that could slow the rate of retinal degeneration in Goldmann-Favre syndrome (GFS).
Protheragen is dedicated to advancing the development of diagnostics and therapeutics for rare diseases like Goldmann-Favre syndrome. Protheragen offers a comprehensive suite of services to support research and development efforts in this area.
Protheragen provides extensive preclinical research services, which are critical for understanding the pathophysiology of GFS and evaluating the potential of new therapeutic interventions. If you are interested in our services, please feel free to contact us.
Reference
Copyright © 2025 Protheragen. All rights reserved.